Genmab — Maj 2014
-
possible that gazyva impacts arzerra sales - it is likely, as expected
-
ibrutinib og idelalisb tager også deres del - men det er ikke her Jan ser markedet. Det er i kombo, hvor han ser Arzerra som stærkeste kombo-partner
-
spectacular pre-clinical studies
-
vil blive præsenteret during sumemr time
-
in major conferences
-
GEN har haft a no of interactions with regulators
-
hopefully in broad label - interactions productive
-
expects decision during summer
-
Sachin fra Kempen
-
spørger til opfattelsen af ibrutinib i markedet
-
Monoterapi med ibrutinib vil få plads i double refrac pga letheden - top oncologist siger at markedet er i komboer
-
de tror markedet bliver small molecules + cd20
-
ser opdaterede data ibrutinib+arzerra til asco - skulle give 100% ORR
-
det var det
-
mon ikke der har været noget periodiseringshalløj ind over det?
-
men spændende at høre, at dara kører hurtigere end selv Jan havde forestillet sig
-
Og så lovede Jan jo næsten fænomenale dara date til Asco...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind